{"id":"W2920859248","doi":"10.1200/jco.2015.33.15_suppl.e13021","title":"Clinical outcomes of patients with gliomas treated with bevacizumab in British Columbia (BC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Temozolomide; Internal medicine; Progression-free survival; Cancer; Glioma; Etoposide; Lomustine; Oncology; Radiation therapy; Chemotherapy; Cyclophosphamide; Vincristine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003224202,0.0001941265,0.0004618198,0.001057494,0.001100621,0.0007956431,0.0005837501,0.0003977356,0.001324165],"category_scores_gemma":[0.001598335,0.0001869162,0.0002876022,0.003385734,0.0003319495,0.0002442433,0.000422027,0.0004915611,0.0002673757],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00995316,"about_ca_system_score_gemma":0.006676466,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8141908,"about_ca_topic_score_gemma":0.8847511,"domain_scores_codex":[0.9995458,0.00003418038,0.00006281813,0.0000722186,0.0001859276,0.00009913036],"domain_scores_gemma":[0.9984323,0.00008159246,0.0005093638,0.00002709725,0.0007017666,0.0002477883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003400745,0.00005118456,0.9892625,0.0002098401,0.00008997669,0.0003982321,0.0002981325,0.00008519398,0.0002485054,0.00002317641,0.002055354,0.006937772],"study_design_scores_gemma":[0.00002711005,0.0001014256,0.996626,0.0001045868,0.00007862889,0.0004667638,0.0005271693,0.0001016604,0.0000791665,0.00002170847,0.001856198,0.000009621138],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822307,0.003819417,0.00004632004,0.0004020894,0.00001793729,0.0001509871,0.009180773,0.000008407382,0.004143365],"genre_scores_gemma":[0.99354,0.001438303,0.00006565438,0.0001830001,0.000009909238,0.00006560637,0.003876876,0.000003963825,0.0008167021],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1858092,"threshold_uncertainty_score":0.3738069,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0844184738330545,"score_gpt":0.4198597781349609,"score_spread":0.3354413043019064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}